Experimental and clinical evidence of neuroprotection by nerve growth factor eye drops: Implications for glaucoma

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 32, 2009, Pages 13469-13474

  Lambiase, Alessandro ^a   Aloe, Luigi ^b   Centofanti, Marco ^c,d   Parisi, Vincenzo ^d   Mantelli, Flavio ^a   Colafrancesco, Valeria ^d   Manni, Gian Luca ^c,d   Bucci, Massimo Gilberto ^c,d   Bonini, Stefano ^a   Levi Montalcini, Rita ^e  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b CNR   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d IRCCS FONDAZIONE BIETTI   (Italy)

^e EUROPEAN BRAIN RESEARCH INSTITUTE   (Italy)

Author keywords

NGF; Optic nerve; Retina

Indexed keywords

NERVE GROWTH FACTOR; SODIUM CHLORIDE;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BURNING SENSATION; CELL DEATH; CELL LOSS; CELL SURVIVAL; CONTRAST SENSITIVITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; EYE BURNING; FEMALE; FOLLOW UP; FUNCTION TEST; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; INTRAOCULAR PRESSURE ABNORMALITY; MALE; NERVE CELL DEGENERATION; NERVE FUNCTION; NEUROPROTECTION; NONHUMAN; OPTIC NERVE; PRIORITY JOURNAL; RAT; RETINA GANGLION CELL; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL ACUITY; VISUAL FIELD DEFECT;

ANIMALIA; RATTUS;

EID: 69449091997     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0906678106     Document Type: Article

References (44)

1. Kingman S (2004) Glaucoma is second leading cause of blindness globally. Bull World Health Organ 82:887-888.
2. Quigley HA (1996) Number of people with glaucoma worldwide. Br J Ophthalmol 80:389-393.
3. Kwon YH, Fingert JH, Kuehn MH, Alward WL (2009) Primary open-angle glaucoma. N Engl J Med 360:1113-1124.
4. Weinreb RN, Khaw PT (2004) Primary open-angle glaucoma. Lancet 363:1711-1720.
5. Whitcup SM (2008) Clinical trials in neuroprotection. Prog Brain Res 173:323-335.
6. Levin LA (2003) Retinal ganglion cells and neuroprotection for glaucoma. Surv Ophthalmol 48(Suppl 1):S21-S24. (Pubitemid 41126692)
7. Levi-Montalcini R (1987) The nerve growth factor 35 years later. Science 237:1154-1162. (Pubitemid 17124912)
8. Hefti F (1994) Neurotrophic factor therapy for nervous system degenerative diseases. J Neurobiol 25:1418-1435. (Pubitemid 24325066)
9. Verge VM, et al. (1992). Colocalization of NGF binding sites, trk mRNA, and low-affinity NGF receptor mRNA in primary sensory neurons: Responses to injury and infusion of NGF. J Neurosci 12:4011-4022.
10. Olson L, et al. (1991). Intraputaminal infusion of nerve growth factor to support adrenal medullary autografts in Parkinson's disease. One-year follow-up of first clinical trial. Arch Neurol 48:373-381.
11. Seiger A, et al. (1993). Intracranial infusion of purified nerve growth factor to an Alzheimer patient: The first attempt of a possible future treatment strategy. Behav Brain Res 57:255-261. (Pubitemid 24027155)
12. Tuszynski MH, et al. (2005). A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 11:551-555.
13. Carmignoto G, Maffei L, Candeo P, Canella R, Comelli C (1989) Effect of NGF on the survival of rat retinal ganglion cells following optic nerve section. J Neurosci 9:1263-1272. (Pubitemid 19116746)
14. Siliprandi R, Canella R, Carmignoto G (1993) Nerve growth factor promotes functional recovery of retinal ganglion cells after ischemia. Invest Ophthalmol Vis Sci 34:3232-3453. (Pubitemid 23346655)
15. Lambiase A, et al. (1997). Nerve growth factor (NGF) reduces and NGF antibody exacerbates retinal damage induced in rabbit by experimental ocular hypertension. Graefes Arch Clin Exp Ophthalmol 235:780-785. (Pubitemid 27514275)
16. Lambiase A, Rama P, Bonini S, Caprioglio G, Aloe L (1998) Topical treatment with nerve growth factor for corneal neurotrophic ulcers. N Engl J Med 338:1174-1180. (Pubitemid 28180745)
17. Lambiase A, Tirassa P, Micera A, Aloe L, Bonini S (2005) Pharmacokinetics of conjunctivally applied nerve growth factor in the retina and optic nerve of adult rats. Invest Ophthalmol Vis Sci 46:3800-3806. (Pubitemid 44264689)
18. Lambiase A, et al. (2007). Nerve growth factor eye drop administrated on the ocular surface of rodents affects the nucleus basalis and septum: Biochemical and structural evidence. Brain Res 1127:45-51. (Pubitemid 44873000)
19. Parisi V, et al. (2001). Correlation between optical coherence tomography, pattern electroretinogram, and visual evoked potentials in open-angle glaucoma patients. Ophthalmology 108:905-912. (Pubitemid 32374247)
20. Morrison JC, et al. (1997).Arat model of chronic pressure-induced optic nerve damage. Exp Eye Res 64:85-96.
21. Coassin M, et al. (2008). Retinal p75 and bax overexpression is associated with retinal ganglion cells apoptosis in a rat model of glaucoma. Graefes Arch Clin Exp Ophthalmol 246:1743-1749.
22. Fortune B, et al. (2004). Selective ganglion cell functional loss in rat with experimental glaucoma. Invest Ophthalmol Vis Sci 45:1854-1862. (Pubitemid 38868982)
23. la Sala A, Corinti S, Federici M, Saragovi HU, Girolomoni G (2000) Ligand activation of nerve growth factor receptor TrkA protects monocytes from apoptosis. J Leukoc Biol 68:104-110. (Pubitemid 30679742)
24. Parisi V (2001) Impaired visual function in glaucoma. Clin Neurophysiol, 112:351-358.
25. Parisi V, Miglior S, Manni G, Centofanti M, Bucci MG (2006) Clinical ability of pattern electroretinograms and visual evoked potentials in detecting visual dysfunction in ocular hypertension and glaucoma. Ophthalmology 113:216-228. (Pubitemid 43170770)
26. Collaborative Normal-Tension Glaucoma Study Group (1998) Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 126:487-497.
27. Tatton W, et al. (2003). Hypothesis for a common basis for neuroprotection in glaucoma and Alzheimer's disease: anti-apoptosis by alpha-2-adrenergic receptor activation. Surv Ophthalmol 48 suppl 1:S25-S37. (Pubitemid 41126693)
28. Pomerance GN, Evans DW (1994) Test-retest reliability of the CSV-1000 contrast test and its relationship to glaucoma therapy. Invest Ophthalmol Vis Sci 35:3357-3361.
29. Pizzorusso T, Porciatti V, Tseng J-L, Aebischer P, Maffei L (1997) Transplant of polymer-encapsulated cells genetically engineered to release nerve growth factor allows a normal functional development of the visual cortex in dark-reared rats. Neuroscience 80:307-311. (Pubitemid 27334582)
30. Lodovichi C, Berardi N, Pizzorusso T, Maffei L (2000) Effects of neurotrophinsoncortical plasticity: Same or different? J Neurosci 20:2155-2165. (Pubitemid 30230068)
31. Rohrer B, Korenbrot JI, LaVail MM, Reichardt LF, Xu B (1999) Role of neurotrophin receptor TrkB in the maturation of rod photoreceptors and establishment of synaptic transmission to the inner retina. J Neurosci 19:8919-8930. (Pubitemid 30226713)
32. Shimohama S, et al. (1993). Protective effect of nerve growth factor against glutamate-induced neurotoxicity in cultured cortical neurons. Brain Res 632:296-302. (Pubitemid 24015528)
33. Wiesmann C, de Vos AM (2001) Nerve growth factor: Structure and function. Cell Mol Life Sci 58:748-759. (Pubitemid 32553032)
34. Lu B (2004) Acute and long-term synaptic modulation by neurotrophins. Prog Brain Res 146:137-150.
35. Tirassa P, Triaca V, Amendola T, Fiore M, Aloe L (2003) EGF and NGF injected into the brain of old mice enhance BDNF and ChAT in proliferating subventricular zone. J Neurosci Res 72:557-564. (Pubitemid 36578641)
36. Liberini P, Cuello A-C (1994) Effects of nerve growth factor in primate models of neurodegeneration: Potential relevance in clinical neurology. Rev Neurosci 5:89-104. (Pubitemid 24231040)
37. Bregman BS, et al. (2002). Transplants and neurotrophic factors increase regeneration and recovery of function after spinal cord injury. Prog Brain Res 137:257-273.
38. Di Fausto V, Fiore M, Tirassa P, Lambiase A, Aloe L (2007) Eye drop NGF administration promotes the recovery of chemically injured cholinergic neurons of adult mouse forebrain. Eur J Neurosci 26:2473-2480. (Pubitemid 350050448)
39. McKinnon SJ (2003) Glaucoma: Ocular Alzheimer's disease? Front Biosci 8:s1140-1156.
40. Kong GY, Van Bergen NJ, Trounce IA, Crowston JG (2009) Mitochondrial dysfunction and glaucoma. J Glaucoma 18:93-100.
41. Bocchini V, Angeletti PU (1969) The nerve growth factor: Purification as a 30,000- molecular-weight protein. Proc Natl Acad Sci USA 64:787-794.
42. Blumenthal E-Z, Sapir-Pichhadze R (2003) Misleading statistical calculations in faradvanced glaucomatous visual field loss. Ophthalmology 110:196-200. (Pubitemid 36068745)
43. (1994) The Advanced Glaucoma Intervention Study (AGIS): 1. Study design and methods and baseline characteristics of study patients. Control Clin Trials 15:299-325.
44. Lachenmayr BJ, Vivell PMO (1993) in Perimetry and its clinical correlation (Thieme Medical Publisher Inc, New York), pp 12-13.